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Dialysis modality and the risk of allograft thrombosis in adult Allograft vascular thrombosis is a catastrophic compli-
renal transplant recipients. cation of kidney transplantation. Graft thrombosis is the
Background. Renal vascular thrombosis (RVT) is a rare but most common in the early postoperative period, often
catastrophic complication of renal transplantation. Although
presenting as primary nonfunction or oligoanuric grafta plethora of risk factors has been identified, a large proportion
dysfunction. Renal angiography or surgical explorationof cases of RVT is unexplained. Uremic coagulopathy and
dialysis modality may predispose to RVT. We investigated the of the allograft bed [1, 2] establishes a definite diagnosis.
impact of the pretransplant dialysis modality on the risk of There is no effective treatment, and in most cases, trans-
RVT in adult renal transplant recipients. plant nephrectomy is required [2–5]. Graft loss caused
Methods. Renal transplant recipients (age 18 years or more)
by primary renal vascular thrombosis (RVT) affects 0.4who were enrolled in the national registry between 1990 and
to 7.0% of renal transplants, accounting for a significant1996 (N 5 84,513) were evaluated for RVT occurring within
proportion of early graft losses [2, 6–11].30 days of transplantation. Each case was matched with two
controls from the same transplant center and with the year of In addition to the well-established systemic hypercoa-
transplantation. The association between RVT and 18 factors gulable states, other risk factors for RVT include techni-
was studied with multivariate conditional logistic regression. cal problems during organ procurement and vascularResults. Forty-nine percent of all cases of RVT (365 out of
anastomosis, acute rejection, extremes of donor age,743) occurred in repeat transplant recipients with an adjusted
perioperative hemodynamics, multiple donor renal ar-odds ratio (OR) of 5.72 compared with first transplants (P ,
0.001). There were a significantly higher odds of RVT in perito- teries, primary cause of end-stage renal disease (ESRD),
neal dialysis (PD)-compared with hemodialysis (HD)-treated pretransplant thrombocytosis, high hematocrit and use
patients (OR 5 1.87, P 5 0.001). Change in dialysis modality of erythropoietin, and a history of prior renal trans-
was an independent predictor of RVT: switching from HD to
plantation [2, 8, 11–18]. Several investigators have re-PD (OR 5 3.59, P , 0.001) and from PD to HD (OR 5 1.62,
ported a threefold to fourfold increase in the incidenceP 5 0.047). Compared with primary transplant recipients on
of RVT in renal transplant recipients treated withHD (OR 5 1.00), the highest odds of RVT were in repeat
transplant recipients treated with PD (OR 5 12.95, P , 0.001) cyclosporine (CsA) when compared with recipients who
and HD (OR 5 4.50, P , 0.001). Other independent predictors received only azathioprine and prednisone [2, 9, 12, 19].
of RVT were preemptive transplantation, relatively young and More recently, attention has been drawn to antiphospho-old donor age, diabetes mellitus and systemic lupus erythema-
lipid antibody syndromes, factor V Leiden mutation, andtosus as causes of end-stage renal disease, recipient gender,
hyperhomocysteinemia as possible causes of RVT [4, 6,and lower panel reactive antibody levels (PRAs).
Conclusions. The strongest risk factors for RVT were re- 20–24].
transplantation and prior PD treatment. Prevention of RVT Despite the plethora of risk factors, a significant pro-
with perioperative anticoagulation should be studied in pa- portion of RVT occurs in the absence of any established
tients who have a constellation of the identified risk factors.
risk factors, suggesting the possibility of unidentified pre-
disposing factors. Peritoneal dialysis (PD) has been im-
plicated as an etiological factor for RVT [25]. PD mayKey words: kidney transplantation, renal graft, uremic coagulopathy,
hemodialysis, perioperative anticoagulation, vascular thrombosis. be a predisposing factor to RVT by causing diffuse eleva-
tion of the activities of plasma procoagulant factors [26].Received for publication May 4, 1998
In addition, patients receiving PD demonstrate increasedand in revised form November 19, 1998
Accepted for publication December 29, 1998 hemostatic tendency because of hemoconcentration re-
sulting from efficient control of extracellular volume 1999 by the International Society of Nephrology
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(ECV) [27]. However, any role of pretransplant PD has on HD (group V) or PD (group VI), and preemptive
renal transplantation without preceding dialysis (groupremained controversial because several studies have
found no association between the mode of pretransplant VII).
The multivariate analysis was based on the conditionaldialysis and RVT [7, 28, 29].
The purpose of this study was to investigate the risk logistic regression for matched case-control data in which
the log odds of RVT were the dependent variables. Thefactors associated with RVT in adult renal transplant
recipients who were registered in the national transplant independent variables (N 5 18) were pretransplant dial-
ysis modality and duration; donor age, gender, race andand dialysis database. We specifically address the ques-
tion of whether pretransplant PD is associated with an cause of death; donor type (living vs. cadaveric); recipi-
ent age, race, gender, and cause of ESRD; HLA match-increased risk of RVT compared with hemodialysis
(HD). ing; cold and warm ischemia time; historical peak panel
reactive antibody level (PRA); donor/recipient cytomeg-
alovirus antibody (CMV) match; recipient body mass
METHODS
index; history of prior renal transplant; and history of
The study was based on transplant data collected by preemptive transplantation.
the United Network for Organ Sharing (UNOS) and the The odds ratio (OR) of RVT and the corresponding
dialysis treatment data in the U.S. Renal Data System 95% confidence intervals were obtained from the condi-
(USRDS). We identified all cases of early (30 days or tional logistic regression model according to the follow-
less) graft failure in renal transplants performed between ing derivation: Odds 5 1/{1 1 exp [2(b0 1 b1x1 1 . . .
1990 and 1996. Case definition was based on the individ- . . . 1 bjxj)]} and the log (OR) for RVT 5 b1(xC1 2
ual transplant center report to the UNOS on the kidney xN1) 1 b2 (xC2 2 xN2) for case (C) versus control (N).
transplant recipient registration and follow-up forms, The notation xj is the value of the predictor variable of
which were completed at the time of kidney transplanta- interest “j,” and bj is its coefficient in the logistic model.
tion, after discharge from the transplant hospitalization, The value xj was either the original value of the charac-
and during follow-up. A study case was defined as graft teristic “j” or an indicator of the level of its classification.
loss occurring within 30 days of renal transplantation, Several variables were classified according to ranges. For
with the primary cause of graft loss coded as “renal example, donor age was classified as 0 to 6, 7 to 12, 13
vascular thrombosis.” Each case was matched with two to 44, 45 to 54, and 55 years or more. The choice of
controls (1:2 matching). The controls chosen for each the reference group was based on natural order of the
case were renal transplants performed at the same trans- variable or the largest category; for example, for cold
plant center and in the same year. The pretransplant ischemia time, 0 to 12 hours was used as the reference
dialysis modality, sequence, and duration of dialysis with an assigned OR of 1.00. An OR greater than 1.00
modality for each case and its controls were identified indicates increased risk for RVT, and an OR less than
in the ESRD modality sequence database. Multiorgan 1.00 suggests a protective effect against RVT relative to
transplant recipients and those younger than 18 years at the reference group.
the time of transplantation were excluded from the study.
From a total of 751 index cases, we excluded eight pa-
RESULTStients who were missing essential data, leaving 743 eligi-
ble cases for whom 1486 appropriate controls were se- Between 1990 and 1996, a total of 84,513 solitary renal
transplants were performed in recipients aged 18 yearslected. A matching ratio of one case to two controls was
successfully accomplished in all cases. Six controls were or more. The study sample (total N 5 2223) consisted of
743 cases of RVT and 1480 controls from 171 transplantexcluded because of missing data. The final study sample
(N 5 2223) consisted of 743 cases and 1480 controls. programs. At the time of transplantation, 67.0% of study
subjects (N 5 1489) were receiving maintenance HD;Univariate analysis of baseline characteristics was per-
formed with the chi-square (categorical variables) and 22.6% (N 5 502) were on PD, and 10.4% (N 5 231)
received preemptive renal transplantation. The inci-the t-test (continuous variables). In order to obtain a
clear measure of the association between pretransplant dence of RVT in the first 30 days after transplantation
was 0.89% (N 5 751). RVT accounted for 17.4% of alldialysis mode and RVT, we used a noninteractive multi-
variate model in which the study subjects were divided graft failures in that period. Sixteen percent of the cases
of RVT (N 5 107) occurred within the first 24 hours ofinto seven groups according to their pretransplant mod-
ality history and sequence (Table 1). The seven study the transplant procedure, with the cumulating frequency
rising to 62 and 89% by postoperative day 10 and 20,groups were primary transplant recipients who had been
treated with HD only (group I) or with PD only (group respectively. The median time from transplantation to
RVT was eight days.II), had switched from HD to PD (group III) or from
PD to HD (group IV), repeat renal transplant recipients Table 2 shows the distribution of baseline characteris-
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Table 1. Classification of study subjects according to pretransplant dialysis modality and prior renal transplant status
Cases Controls
Prior renal Mean duration of
Study group Subjects transplant N (%) dialysis months
I HD No 161 (7.2) 690 (31.0) 27.4 (631.6)
II PD No 63 (2.8) 142 (6.4) 17 (615.6)
III Switched from HD to PD No 60 (2.7) 75 (3.4) 30.1 (627.3)
IV Switched from PD to HD No 32 (1.4) 85 (3.8) 25.2 (629.8)
V HD Yes 249 (11.2) 272 (12.2) 30.1 (623.7)
VI PD Yes 116 (5.2) 46 (2.1) 32.0 (630.5)
VII No prior dialysis No 62 (2.8) 170 (7.7)
All 743 (33.4) 1,480 (66.6) 27.9 (629.9)
tics between cases and controls. The study groups were 96-hours post-transplantation. In this series of early cases
unbalanced with respect to several baseline characteris- (N 5 289, 39% of all cases) and their controls, the excess
tics, including the pretransplant mode of dialysis, dura- risk of RVT with PD relative to HD was also evident
tion of dialysis, recipient age, the number of HLA DR (RR 5 2.60, P 5 0.004).
mismatches, and cold ischemia time. The cases were Forty-nine percent of all cases of RVT occurred in
more likely to be on PD, had longer periods of pretrans- repeat transplant recipients. The risk of RVT among
plant dialysis, were slightly younger at transplantation, repeat transplant patients varies by dialysis modality.
had longer cold ischemia times, and had a statistically Using primary transplant recipients on HD as the refer-
greater number of HLA DR mismatches. ence group (OR 5 1.00), repeat transplant recipients on
There were substantial differences among the study HD had an OR of 4.50 (P , 0.001), and those on PD
groups with respect to the mode and the duration of had an OR of 12.95 (P , 0.001). Thus, the joint effect
dialysis prior to transplantation (Table 1). Among pri- of PD and retransplantation appears to be synergistic
mary transplant recipients, PD-treated patients tended (multiplicative) on the risk of RVT.
to have spent less time on dialysis prior to transplantation Patients who underwent kidney transplantation with
(17.0 6 15.6 months) compared with 27.4 6 31.6 months no prior dialysis history (preemptive transplantation,
for HD-treated patients (P , 0.001). There was little study group VII) had a higher likelihood of RVT (OR 5
difference in the duration of dialysis treatment between 1.66, P 5 0.008) compared with primary transplant recip-
HD and PD among repeat transplant recipients. ients treated with only HD before transplantation.
The results of the multivariate analysis of the risk of Donor age was associated with RVT in a nonlinear
RVT are shown in Table 3. Using patients receiving fashion. The donor age effect was highest at the youngest
pretransplant HD as the reference group (OR 5 1.00),
and oldest ages. Compared with donor ages 13 to 44
primary transplant recipients on PD at the time of trans-
years (OR 5 1.00), organs from the youngest donorsplantation had a significantly higher risk of RVT (OR 5
(age 0 to 6 years) were more than twofold as likely to1.87, P 5 0.001). A change of dialysis modality was also
have RVT (OR 5 2.48, P , 0.001). The likelihood ofan independent predictor of RVT. Among primary renal
RVT in other donor age groups was 7 to 12 years (OR 5transplant recipients, switching from HD to PD was the
1.57, P 5 0.052), 45 to 54 years (1.40, P 5 0.028), andstrongest predictor of RVT. When the pretransplant dial-
more than 55 years (OR 5 1.95, P , 0.001).ysis modality switch was from HD to PD, the odds of
The primary cause of ESRD may predispose to hyper-RVT was more than threefold higher than that of HD
coagulability. In this study, patients with ESRD causedpatients who never switched (OR 5 3.59, P , 0.001).
by systemic lupus erythematosus (SLE) and diabetesPrimary renal transplant recipients who switched from
mellitus were more likely to suffer RVT. Compared withPD to HD had an odds ratio of RVT that was 62%
patients whose ESRD was due to hypertension, the ad-higher than that of HD patients, who never switched
justed OR for SLE was 1.75 (P 5 0.050) and 1.58 fordialysis modality (OR 5 1.62, P 5 0.047).
diabetes mellitus (P 5 0.007). There was no significantAllograft thrombosis is most likely to occur in the first
association between RVT and other causes of ESRD,few days after transplantation; therefore, the certainty
including glomerulonephritis not caused by SLE, poly-of diagnosis is greatest for the early cases. Because we
cystic kidney disease, and obstructive uropathy.could not confirm that all reporting transplant centers
Other factors found to be associated with RVT wereverified their diagnosis of RVT with renal angiography
peak PRAs and recipient gender. Compared with a PRAor surgical exploration, we performed a subanalysis of
of 0%, recipients with PRA levels greater than 10% hadsubjects who were most likely to be true cases of RVT,
that is, those in which the diagnosis was made in the first a significantly lower likelihood of allograft thrombosis.
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Table 2. Baseline characteristics of cases and controls
Cases (% or sd) Controls (% or sd)
Characteristic N 5 743 N 5 1,480 P-value
Pretransplant dialysis modality
Hemodialysis 442 (59.5) 1,047 (70.7) 0.001
Peritoneal dialysis 239 (32.2) 263 (17.8) 0.001
Preemptive transplantation 62 (8.3) 170 (11.5) 0.681
Duration of dialysis months 28.2 (631.1) 23.6 (629.4) 0.011
Mean recipient age years 41.1 (612.9) 42.7 (612.6) 0.010
Male recipient 389 (52.4) 817 (59.9) 0.001
Recipient race
White 575 (77.4) 1,068 (72.1) 0.008
African American 145 (19.5) 330 (22.3) 0.131
Other race 23 (3.1) 82 (5.5) 0.010
Primary cause of ESRD
Glomerulonephritis 211 (28.4) 405 (27.4) 0.740
Hypertension 86 (11.6) 222 (15.0) 0.027
Diabetes mellitus 194 (26.1) 311 (21.0) 0.007
Other 252 (33.9) 542 (36.6) 0.209
Peak PRA 16.4 (627.0) 17.4 (627.8) 0.907
Mean donor age 32.6 (618.0) 33.5 (615.5) 0.750
% Male donors 410 (55.2) 879 (59.3) 0.058
Living donors 120 (16.2) 304 (20.5) 0.013
Donor race
White 637 (85.7) 1,283 (86.7) 0.536
African American 87 (11.7) 147 (9.9) 0.198
Other race 14 (1.9) 36 (2.43) 0.411
Donor cause of death
Anoxia 48 (6.5) 78 (5.3) 0.252
Cerebrovascular accident 218 (29.3) 387 (26.2) 0.111
Head trauma 200 (26.9) 392 (26.5) 0.828
Other causes 152 (20.5) 309 (20.9) 0.817
HLA matching
A,B
0 33 36 0.174
1–2 53 51 0.350
3–4 14 13 0.605
DR
0 51 56 0.036
1 33 31 0.339
2 16 13 0.092
Cold ischemia time hours 20.3 (612.5) 18.7 (612.8) 0.021
Warm ischemia time minutes 28.0 (622.2) 28.7 (623.3) 0.200
Antibody induction therapy 262 (35.3) 514 (34.7) 0.804
Percentages were rounded to the nearest 0.1. Percentages may not add up to 100% for each variable because of rounding and missing values. Values in parentheses
indicate one standard deviation (sd) for continuous variables and percentages for categorical variables.
Female recipients had a 46% higher likelihood of RVT of transplant center and year of transplantation was to
reduce bias from comparisons across centers and be-(OR 5 1.46, P , 0.001).
tween transplants performed at different time periods.The multivariate analysis showed no significant associ-
This study found a combined incidence of renal allo-ation between renal allograft thrombosis and any of the
graft arterial and venous thrombosis of 0.9%, which isfollowing factors: recipient’s age, race, or body mass
at the lower end of the incidence rates in studies in whichindex; donor cause of death, race, or gender; donor
the diagnosis of vascular thrombosis was confirmed bysource (cadaveric versus living); HLA matching; cold
angiography or surgical exploration. These studies haveischemia time; warm ischemia time; donor/recipient
reported incidence rates ranging from 1.0 to 7.3% (TableCMV match status; and organ preservation technique.
4). The wide variance in the reported incidence of RVT
reflects large differences in both the risk periods covered
DISCUSSION by various studies and the number of subjects studied.
This case-control study is the largest series of renal In general, larger series tended to report lower incidence
allograft vascular thrombosis in adult transplant recipi- rates (Table 4). In addition, several investigators have
ents. Because of its low incidence in individual programs, reported a twofold to threefold higher incidence of RVT
RVT is most suited for a case-control investigation of in the pediatric population. Hence, different estimates
are reported depending on the pediatric mix of the seriesregistry data [30]. The objective of matching on the basis
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Table 3. Factors associated with early renal allograft thrombosis in Peritoneal dialysis patients have significantly higher
adult kidney transplant recipientsa
concentration of apolipoprotein(a) [Apo(a)], which is
Variable Odds ratio 95% C.I.b P value the thrombogenic plasminogen-like moiety of lipopro-
Primary transplant tein(a) [34]. Apo(a) has sequence homology with plas-
HD 1.00 — refc minogen, and although it has the ability to bind fibrin
PD 1.87 1.28–2.72 0.001
and plasminogen receptors, it lacks significant fibrino-Switched from HD to PD 3.59 2.36–5.46 ,0.001
Switched from PD to HD 1.62 1.00–2.61 0.047 lytic properties [35, 36]. In addition, significantly higher
Repeat transplant (overall) 5.72 4.40–7.45 ,0.001 procoagulant activities of factors II, VII, VIII, IX, X, XI,HD 4.50 3.41–5.93 ,0.001
and XII without a concomitant alteration of endogenousPD 12.95 8.31–20.19 ,0.001
Preemptive transplantation 1.66 1.14–2.43 0.008 anticoagulants such as antithrombin III and protein C
Female recipient 1.46 1.18–1.81 ,0.001 have been found in PD-treated patients [26]. The diffusePrimary cause of ESRD
elevation of plasma procoagulant factor activities unop-Hypertension 1.00 — ref
Diabetes mellitus 1.58 1.13–2.22 0.007 posed by any increase in endogenous fibrinolytic or anti-
Systemic lupus erythematosus 1.75 1.01–3.05 0.050 coagulant activity places PD patients at an increased riskDonor age years
of thrombosis [26].0–6 2.48 1.49–4.14 0.001
7–12 1.57 1.00–2.48 0.052 Some of the thrombotic traits described in PD patients
13–44 1.00 — ref
may also be present in HD patients [37, 38]. In fact,45–54 1.40 1.04–1.89 0.028
551 1.95 1.35–2.80 ,0.001 some investigators have found a greater thrombotic ten-
Peak panel reactive antibodies % dency in HD compared with PD patients [39]. However,
0 1.00 — ref
the preponderance of evidence suggests that the HD1–10 1.01 0.77–1.34 0.933
11–50 0.69 0.49–0.94 0.020 procedure is attended by several antithrombotic events,
51–100 0.65 0.45–0.95 0.026 including exogenous heparin administration during dial-
a Odds ratio was calculated with the conditional logistic regression for matched ysis sessions and the use of antiplatelet drugs to prevent
case-control. Covariates adjusted for in the logit model include those listed above
vascular access occlusion. Furthermore, endogenous tis-in addition to recipient age and race; donor race, gender and cause of death;
recipient body mass index at transplantation; donor type (living vs. cadaveric); sue-type plasminogen activator (tPA) is released in mea-
donor/recipient CMV match status; cold and warm ischemia times; organ preser-
vation technique and HLA matching surable quantities during the HD session, which then
b Indicates confidence interval results in a demonstrable acceleration of fibrinolytic ac-c Indicates reference group
tivity [38, 40].
Hemoconcentration is a risk factor for vascular throm-
bosis [33]. A higher hematocrit level resulting from re-
duction in ECV is more likely in PD compared withstudied [7–9, 11, 17, 19, 31–33]. Allowing for the exclu-
sion of pediatric cases, the incidence of 0.9% found in HD patients [41]. Elegant physiological studies using
molecular markers of the hydration state have also foundthis study compares favorably with the rates found in
larger series in which the diagnosis was confirmed by significantly lower ECV in PD compared with HD pa-
tients [42]. In ESRD patients, blood pressure control isangiography and/or surgical exploration (Table 4).
We found that recipients with RVT were significantly a correlate of the degree of ECV expansion because
hypertension in this setting is partly dependent on vol-more likely to have received pretransplant PD than HD.
The excess risk associated with PD was further accentu- ume status [43, 44]. Several lines of evidence suggest that
PD patients were at greater risk of hemoconcentration.ated after controlling for other confounding variables.
This finding is consistent with the report by Murphy et First, in contrast to the wide swings in ECV associated
with intermittent HD, ECV is more stable and easilyal [25]. In a retrospective study of 202 renal transplants,
all nine cases of RVT were found in patients on PD at adjusted with PD treatment [45]. Second, more effective
ECV reduction in PD has been associated with a con-the time of transplantation. In a corroborating report
from the European Dialysis and Transplantation Regis- comitant reduction in blood pressure and the number of
antihypertensive medications compared with HD [27,try (EDTA) data, the incidence of renovascular graft
thrombosis in PD patients was 7.1% compared with 1.8% 45–47]. Third, HD patients have been found to have
lower blood pressures after switching to PD [48]. Thein HD patients [25].
The higher risk of RVT in PD-treated patients is con- effective reduction of ECV in PD patients may be
achieved at the expense of reduced plasma volume withsistent with an acquired thrombophilic state. The mecha-
nism by which PD may predispose to increased systemic an increased propensity to hemoconcentration. Al-
though a number of investigators have reported lowerthrombophilia has not been fully elucidated. However,
a number of studies have identified several hemostatic systolic and diastolic blood pressure loads and therefore
lower ECV in HD patients, the confounding effect ofabnormalities favoring increased thrombogenesis in PD
patients. undertreatment of PD patients and consequent volume
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Table 4. Reported incidence of early macrovascular renal allograft thrombosisa
Overall incidence Maximum
Arterial thrombosis Venous thrombosis of graft thrombosis post-transplant days
Author, year Number (N) of to diagnosis of
[reference number] renal transplants N (%) RVTb,c
Bakir, 1996 [10] 558 11 (1.9) 19 (3.4) 34 (6.0) 15
Benoit, 1994 [23] 200 4 (2.0) 1 (0.5) 5 (2.5) —
Dodhia, 1991 [3] 136 6 (4.4) — — 33
Gruber, 1989 [61] 224 0 (0.0) 3 (1.3) 3 (1.3) 11
Jones, 1988 [9] 110 2 (1.8) 6 (5.5) 8 (7.3) —
Ismail, 1997d [7] 176 3 (1.7) 4 (2.3) 7 (4.0) 14
Laupacis, 1983 [19] 291 4 (1.4) — — —
Louridas, 1987 [4] 909 3 (0.3) 6 (0.7) 9 (1.0) —
Merion, 1984 [56] 108 2 (1.9) 4 (3.7) 6 (5.7) 30
Merion, 1985 [2] 168 — 7 (4.2) — 8
Murphy, 1994 [25] 202 2 (1.0) 7 (3.5) 9 (4.5) —
Nerstrøm, 1973 [5] 155 3 (1.9) 5 (3.2) 8 (5.2) —
Palleschi, 1980 [32] 600 5 2 7 (1.2) 16
Penny, 1994 [55] 6,153 70 (1.1) 64 (1.0) 134 (2.2) 30
Rijksen, 1982 [1] 400 7 (1.8) 2 (0.5) 9 (2.3) 28
Rigotti, 1986 [12] 622 6 (1.0) — — 12
van Lieburg, 1995d [33] 100 4 (4.5) 7 (7.5) 12 (12.0) 6
van Roye, 1993 [13] 1,300 11 (0.9) 17 (1.3) — —
Vidne, 1976 [31] 202 4 (2.0) 1 (0.5) 5 (2.5) 42
a Diagnosis of RVT was established by angiography and/or surgical exploration in all the series
b Longest time to event from postoperative day in each series
c The overall incidence may be higher than the sum of arterial and venous thromboses because of cases with both renal and arterial thromboses
d Pediatric cases only
overload was not taken into account in these studies ric recipients without prior dialysis compared with 2.8%
in recipients who had been on pretransplant mainte-[49–51].
Peritoneal dialysis patients may also be at an increased nance dialysis. Preemptive transplant recipients may
have an increased risk of RVT as a result of perioperativerisk of renal allograft vascular thrombosis because the
choice of PD as a modality of treatment may not be intravascular volume depletion secondary to high urine
output from the native kidneys [33].independent of other thrombotic risk factors. Studies
have shown that patients with prothrombotic comorbid The strong association between the history of prior
renal transplantation and RVT has been shown in previ-conditions such as low output cardiac failure, atheroscle-
rotic heart disease, and vascular access problems may ous studies [8, 11]. It is not clear whether immunological
mechanisms underlie the predisposition to RVT in re-have been preferentially selected to PD either at the
onset of ESRD or after technique failure on HD [52–54]. peat kidney transplant recipients.
Transplant recipients who developed RVT were moreIndeed, we found that switching from HD to PD, which
in itself may be an indicator of vascular access problem likely than controls to have received kidneys from donors
in the extremes of age. This is in agreement with theor atherosclerotic disease, is the strongest risk factor for
RVT in primary renal transplant recipients. findings by others [8, 9, 11, 55]. In one series, 33% of
cases of renal vein thrombosis occurred in kidneys fromEnd-stage renal disease (ESRD) due to systemic lupus
erythrematosus (SLE) and diabetes mellitus was pre- very young donors (#6 years old) [9]. In pediatric recipi-
ents, donor age was shown to have a linear inverse rela-dictive of RVT. The association with SLE is mostly likely
due to antiphospholipid antibody syndrome, which has tionship to RVT [8, 11], but we observed a nonlinear
relationship with highest risks in donors age 0 to 6 yearsbeen implicated as a cause of allograft thrombosis in
SLE patients undergoing renal transplantation [6, 22]. and 55 years or more. The donor age effect may be
mediated by technical difficulties associated with the pro-The diffuse atherosclerotic process in large blood vessels
may explain the disposition to RVT in patients who curement and implantation of kidneys from young do-
nors and progressive atheromatous lesions in older do-developed ESRD secondary to diabetes mellitus.
The finding of an increased likelihood of graft throm- nors.
Several investigators have reported a dramatic in-bosis among recipients undergoing preemptive renal
transplantation is consistent with the observation in pedi- crease in the incidence of RVT among CsA-treated renal
transplant recipients when compared with recipientsatric recipients [11, 33]. Analysis of data from the North
American Pediatric Renal Transplant Cooperative Study treated with prednisone and azathioprine only [12, 19,
56]. CsA is the mainstay of maintenance immunosup-showed a graft thrombosis incidence of 12.5% in pediat-
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pression in more than 90% of renal transplant recipients. tus. In the absence of an effective treatment for RVT,
Thus, a small elevation of risk could have a large impact preventive strategies are of paramount importance. At-
on the incidence of RVT. CsA has numerous procoagu- tention to intravascular volume status may be critical in
lant properties, including the inhibition of prostacyclin preventing RVT in patients undergoing preemptive re-
production by the vascular endothelium, increased aden- nal transplantation. Additional studies are needed to
osine diphosphate-induced platelet aggregation, release consider future screening for thrombotic risks in patients
of thromboxane A2, generation of thromboplastin, and on PD at the time of renal transplantation. A randomized
increased factor VIII activity [57–60]. Notwithstanding clinical trial of perioperative anticoagulation therapy
these prothrombotic properties, some large studies have with an 85% power to detect a 20% reduction in risk of
not found an elevated risk of RVT in CsA-treated trans- RVT would require 3700 high-risk patients. The initia-
plant recipients [4, 10, 14, 33, 61]. Moreover, delayed tion of preventive anticoagulation therapy must await
graft function/primary nonfunction, which is usually the the results of a prospective clinical investigation to test
classic presentation of RVT, often leads to a manage- whether a combination of the identified risk factors in
ment decision to delay the introduction CsA or belated prospective renal transplant recipients constitutes an ap-
initiation of antibody-induction therapy. In concert, we propriate indication for perioperative anticoagulation
found that 37% of cases of RVT were treated with CsA therapy.
compared with 79% among the controls (P 5 0.001). In
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